Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2019.
Minerva has five late-stage clinical efficacy trials ongoing with three product candidates, including a Phase 3 trial with roluperidone (MIN-101) for negative symptoms in patients with schizophrenia, a Phase 2b trial with MIN-117 for major depressive disorder (MDD) associated with anxiety and three Phase 2b trials with seltorexant (MIN-202) for insomnia disorder and MDD.
“I am very pleased to provide an update and insights into the progress we are making in all of our studies,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “We have updated forecast timelines for the roluperidone Phase 3 study and the MIN-117 Phase 2b study, both of which we now expect to read out in the fourth quarter of this year.
“Our three seltorexant studies will now read out sooner than anticipated, with patient enrollment completed in all three,” said Dr. Luthringer. “We expect to report top-line results from both our first MDD trial and our insomnia trial in the second quarter of 2019, and we expect top-line results from our second MDD trial in the third quarter of 2019.
“The new timelines reflect the latest information available from our sites, as well as the care that we are taking both in recruiting subjects who meet stringent entry criteria and in engaging well-trained clinical investigators to evaluate the therapeutic benefit of our product candidates,” said Dr. Luthringer. “I am pleased to report that patient selection to date has met these standards and the investigators are performing well. Our focus continues to be on trial conduct and data quality.”
- The Company is actively enrolling patients in the pivotal Phase 3 trial with roluperidone (clinicaltrials.gov identifier: NCT03397134). Approximately 60 sites in the U.S. and Europe are participating in this trial, and target enrollment is approximately 500 patients. Completion of full enrollment is now expected in the second half of 2019, and top-line results from the 12-week, double-blind portion of the trial are expected in the fourth quarter of 2019.
- In parallel with advancing its Phase 3 study, Minerva is continuing preparatory work for regulatory filing and commercialization. These activities include clinical pharmacology studies and manufacturing of registration batches.
- Pre-clinical data presented at the 2019 Congress of the Schizophrenia International Research Society suggest a mechanistic role for roluperidone in addressing negative symptoms. Presenters also indicated the potential of roluperidone for disease modification and improved neuroplasticity.
Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):
- Three Phase 2b clinical trials are ongoing with seltorexant, including two in MDD and one in insomnia disorder.
- In the first MDD trial, designated as the 2001 trial (Clinicaltrials.gov Identifier: NCT03227224), patient enrollment has been completed, with 287 patients enrolled at clinical sites in the U.S., Europe and Japan. Top-line results from this trial are expected in the second quarter of 2019.
- Enrollment has also been completed in the insomnia trial, designated as the 2005 trial (Clinicaltrials.gov Identifier: NCT03375203), with approximately 360 patients enrolled at clinical sites in the U.S., Europe and Japan. Top-line results are expected in the second quarter of 2019.
- In the second MDD trial, designated as the 2002 trial (Clinicaltrials.gov Identifier NCT03321526), patient enrollment has also been completed, with 100 patients enrolled at clinical sites in the U.S. Top-line results from this trial are expected in the third quarter of 2019.
- A Phase 2b trial is ongoing with MIN-117 to treat patients diagnosed with MDD and associated anxiety disorders (Clinicaltrials.gov Identifier: NCT03446846). Approximately 324 patients are expected to be enrolled at 40 clinical sites in the U.S. and Europe. Completion of enrollment is now expected in the third quarter of 2019, with top-line results expected to be available in the fourth quarter of 2019.
First Quarter 2019 Financial Results
Net Loss: Net loss was $15.8 million for the first quarter of 2019, or a loss per share of $0.41 (basic and diluted), compared to a net loss of $12.4 million for the first quarter of 2018, or a loss per share of $0.32 (basic and diluted).
R&D Expenses: Research and development (R&D) expenses were $11.6 million in the first quarter of 2019, compared to $8.4 million in the first quarter of 2018. The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. R&D expenses are expected to increase during 2019 with increased patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
G&A Expenses: General and administrative (G&A) expenses were $4.7 million in the first quarter of 2019, compared to $4.3 million in the first quarter of 2018. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support the Company’s pre-commercial activities.
- Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2019 were approximately $79.3 million.
Conference Call Information:
Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities. To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 5697837.
The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and Exchange Commission on March 6, 2019. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
|CONDENSED CONSOLIDATED BALANCE SHEET DATA|
|March 31,||December 31,|
|Cash and cash equivalents||$||30,608||$||50,235|
|Prepaid expenses and other current assets||1,054||1,921|
|Total current assets||80,319||90,019|
|Marketable securities - noncurrent||-||-|
|Other noncurrent assets||15||15|
|Operating lease right-of-use assets||371||-|
|In-process research and development||34,200||34,200|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued expenses and other current liabilities||3,721||1,810|
|Total current liabilities||6,903||3,609|
|Other noncurrent liabilities||-||29|
|Noncurrent operating leases||243||-|
|Additional paid-in capital||307,800||304,814|
|Total stockholders' equity||77,424||90,265|
|Total Liabilities and Stockholders' Equity||$||129,803||$||139,136|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
Three Months Ended March 31,
(in thousands, except per share amounts)
|Research and development||11,606||8,449|
|General and administrative||4,706||4,294|
|Total operating expenses||16,312||12,743|
|Foreign exchange losses||(6||)||(18||)|
|Loss before income taxes||(15,827||)||(12,418||)|
|Benefit for income taxes||-||-|
|Net (loss) income||$||(15,827||)||$||(12,418||)|
|Loss per share:|
|Basic and diluted||$||(0.41||)||$||(0.32||)|
|Weighted average shares:|
|Basic and diluted||38,968||38,749|
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
INDKALDELSE til ordinær generalforsamling i FLSmidth & Co. A/S2.6.2020 14:46:17 CEST | pressemeddelelse
Company Announcement No. 10-2020 Bestyrelsen indkalder herved til ordinær generalforsamling fredag den 26. juni 2020 kl. 16.00 på selskabets adresse, Vigerslev Allé 77, 2500 Valby. Af hensyn til alles sikkerhed og for at mindske risikoen for smittespredning af COVID-19 henstiller vi til, at vores aktionærer ikke møder op fysisk på generalforsamlingen, men brevstemmer eller giver fuldmagt og følger generalforsamlingen via livestreaming på hjemmesiden. Ledelsen vil også være meget begrænset repræsenteret for at mindske smitterisikoen. Dagsorden: Bestyrelsens beretning om selskabets virksomhed i 2019Forelæggelse og godkendelse af årsrapport for 2019Godkendelse af honorarer til bestyrelsen: a. Endelig godkendelse af honorarer for 2019 Bestyrelsen foreslår uændret godkendelse af honorarerne for 2019, som blev forhåndsgodkendt af generalforsamlingen i 2019. Honorarerne er baseret på et grundhonorar på DKK 450.000 (”Grundhonoraret”) med dobbelt honorar til næstformanden og tredobbelt honorar
NOTICE TO CONVENE the Annual General Meeting of FLSmidth & Co. A/S2.6.2020 14:46:17 CEST | Press release
Company Announcement No. 10-2020 The Board of Directors hereby convenes the Annual General Meeting to be held on Friday 26 June 2020 at 4 pm (CET) at the offices of the company, Vigerslev Allé 77, DK-2500 Valby. To protect everyone’s safety and reduce the risk of COVID-19 spreading, we recommend that shareholders refrain from attending the general meeting in person and instead cast their votes by postal vote or proxy and attend the live webcast of the general meeting via the web site. The number of representatives from the management will be reduced to reduce the risk of infection. Agenda: The Board of Directors' report on the company’s activities in 2019.Presentation and approval of the 2019 Annual Report.Approval of the Board of Directors’ fees: a. Final approval of fees for 2019. The Board of Directors proposes unchanged approval of the fees for 2019 that were pre-approved by the general meeting in 2019. The fees are based on a base fee of DKK 450,000 (the “Base Fee”) with twice tha
Decisions of Sampo plc’s Annual General Meeting2.6.2020 14:00:00 CEST | Press release
SAMPO PLC DECISIONS OF GENERAL MEETING 2 June 2020 at 3:00 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 2 June 2020, decided to distribute a dividend of EUR 1.50 per share for 2019. The record date for dividend payment is 4 June 2020 and the dividend will be paid on 11 June 2020. The Annual General Meeting adopted the financial accounts for 2019 and discharged the Board of Directors and the CEO from liability for the financial year. The Annual General Meeting elected eight members to the Board of Directors. The following members were re-elected to the Board: Christian Clausen, Fiona Clutterbuck, Jannica Fagerholm, Johanna Lamminen, Risto Murto, Antti Mäkinen and Björn Wahlroos. Georg Ehrnrooth was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting. At its organizational meeting, the Board elected Björn Wahlroos as Chairman and Ja
Cargotec completes the ownership change of joint venture in China2.6.2020 12:00:00 CEST | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 2 JUNE 2020 AT 1 PM (EEST) Cargotec has completed the sale of its share of the joint venture Rainbow-Cargotec Industries Co., Ltd (RCI) in China. As part of the agreement, Cargotec acquired certain operations and assets of the joint venture from Jiangsu Rainbow Heavy Industries Co., Ltd. (RHI), and approximately 160 employees have moved over from RCI to Kalmar. On 11 May 2020, Cargotec announced plans to sell its 49% share of the joint venture to the other owner RHI. RHI now owns 100% of the former joint venture, and the new name of the company is Rainbow Industries Co. Ltd. (RIC). RIC will continue as Cargotec’s subcontractor and provide assembly services for Cargotec’s business areas Kalmar and MacGregor at the factory in Taicang, China. The change aims to simplify Cargotec’s global supply chain operations. Simplification is needed mainly because the number of complex automation projects has been growing in the past couple of years. The arrangemen
Result of Riksbank reversed auctions SEK Municipal Bonds2.6.2020 11:30:00 CEST | Press release
Result of Riksbank reversed auctions SEK Municipal Bonds Results of auctions Municipal BondsAggregateAuction date6/2/2020Maturity2023Tendered volume, mln SEK750 +/- 750Volume offered, mln SEK156Volume bought, mln SEK50Number of bids3Number of accepted bids1Credit Class 1Maturity, QuarterQ1Maturity, QuarterQ2Maturity, QuarterQ3Maturity, QuarterQ4Volume Offered, mln SEK50Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume bought, mln SEK50Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Number of bids1Number of bids0Number of bids0Number of bids0Number of accepted bids1Number of accepted bids0Number of accepted bids0Number of accepted bids0Average yield0.120 %Average yield-Average yield-Average yield-Lowest accepted yield0.120 %Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Highest yield0.120 %Highest yield-Highest yield-Highest yield-% accepted at lowest yield100.00% accepted at lowest yield-% accepted at lowest yield-% a
UPM Plywood is planning to scale down plywood production in Finland2.6.2020 11:00:00 CEST | Press release
(UPM Plywood, Lahti, 02.06.2020 at 12:00) – UPM Plywood is planning to permanently close its Jyväskylä plywood mill, which is producing spruce and birch plywood. The company starts a consultation process concerning the entire personnel working at the mill. UPM Jyväskylä plywood mill employs 167 people. The Profitability of Jyväskylä plywood mill has been weak for a long time, even during periods of high-demand. Despite investments as well as savings and improvement activities, the profitability has not improved to a sustainable level. Competition in the birch plywood market is increasing constantly. New birch plywood capacity has been built especially in Russia, where the production cost level is significantly more competitive than in Finland. If realized, the planned actions would strengthen UPM Plywood’s overall competitiveness and performance in the long run. “In Finland, a full run of the capacity has not been feasible due to the terms in the woodworking industry. In addition, repe